Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
8
×
national blog main
novartis
8
×
seattle blog main
seattle top stories
startups
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
cancer
cancer immunotherapy
eli lilly
abbvie
alzheimer's disease
biogen
gilead sciences
medicare
pfizer
takeda pharmaceutical
What
bio
roundup
drug
acquisitions
ceo
alzheimer’s
biggest
companies
daniel
drugs
gilead
new
o’day
patients
pharmaceutical
price
sciences
typically
aims
albert
announced
approval
bails
biogen’s
biopharmaceutical
bourla
brand
bridgebio
build
buy
capital
car
changes
collabs
company
company’s
congress
convo
covid
crispr
Language
unset
unknown
Current search:
novartis
×
deals
×
startups
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Xealth Gets $11M, Aims to Be Surescripts of Digital Health Services
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel